Here's Why Gilead Sciences (GILD) Gained But Lagged the Market Today
In the latest trading session, Gilead Sciences (GILD) closed at $72.31, marking a +0.29% move from the previous day.
History Says the Nasdaq Will Keep Soaring in 2024 -- and Wall Street Thinks This High-Yield Dividend Stock Could Jump Nearly 20%
Analysts have great expectations for Gilead Sciences over the next 12 months. The biotech has an attractive valuation, a juicy dividend, several drugs with solid momentum, and plenty of cash.
Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Stock Alert: 3 Market Giants on the Brink of Monumental Rallies
During stock market ups and downs, identifying the next big players breeding massive value growth potentials is similar to finding a pearl in a vast ice lake. Among the multitude of options, certai...
Gilead Sciences: 2024 Catalysts Should Drive Growth And Change In Sentiment
Gilead Sciences: 2024 Catalysts Should Drive Growth And Change In Sentiment
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials
Gilead Sciences said on Thursday enrollments to test its cancer drug, magrolimab, on solid tumors had been paused globally, a week after the U.S. regulator put some studies on hold following increa...
Gilead (GILD) to Buy CBAY for $4.3B, Add PBC Drug to Pipeline
Gilead (GILD) is all set to acquire CymaBay Therapeutics for $4.3 billion and strengthen its liver disease portfolio with the addition of seladelpar to its pipeline.
Gilead-backed Kyverna Therapeutics valued at $1.4 bln in stellar debut
Shares of Kyverna Therapeutics jumped 55.7% in their market debut on Thursday, giving the biopharmaceutical company that is backed by Gilead Sciences a market capitalization of $1.4 billion.
Why Gilead Sciences Stock Dropped Today
Gilead delivered a mixed fourth quarter relative to expectations. The biopharma giant also issued underwhelming forward guidance.
Gilead (GILD) Q4 Earnings Miss Estimates, Sales Top on Veklury
Gilead (GILD) posts mixed results for the fourth quarter. Sales beat estimates on the better-than-expected performance of Veklury due to higher hospitalizations at the end of 2023.
Gilead Sciences, Inc. (GILD) Q4 2023 Earnings Call Transcript
Gilead Sciences, Inc. (GILD) Q4 2023 Earnings Call Transcript
Gilead (GILD) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street est...
Gilead Rode An Unexpected Source For Its Sales Beat, But Profit Came Up Short
Gilead came up with a mixed fourth quarter late Tuesday as sales of its Covid treatment bolstered sales. GILD stock slipped in late trades.
Gilead quarterly revenue drops 4%, oral COVID drug fails trial
Gilead Sciences on Tuesday said its fourth-quarter revenue dipped 4% on lower sales of HIV drugs and Veklury, an infused drug for hospitalized COVID-19 patients, while its adjusted profit rose 3% d...
Gilead (GILD) Gears Up to Report Q4 Earnings: Whats in Store?
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its fourth-quarter 2023 results.
Related Companies